Independent presidential candidate and former Minister for Trade and Industry, Alan Kyerematen, has expressed disappointment ...

Today, almost every rural family across the Amazon has a garden. Visit any household and you will find cassava roasting on the fire, being toasted into a chewy flatbread called casabe, fermenting into ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This story appears in the February 2017 issue of National Geographic magazine. If you’re a beermaker in Germany, Martin Zarnkow is a guy you want to know. Students come to his department at the ...

For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s ...

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences SAVA. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Shares of Cassava Sciences Inc. dropped more than 12% in the extended session Thursday U.S. securities regulators announced a settlement with the pharma company, after charging it and two former ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences and its executives agreed to pay $40 million in penalties for misleading investors. Dr. Wang, a consultant, manipulated clinical trial data, leading to misleading Alzheimer's ...

There's nothing quite like a cold, crisp beer on a crisp autumn evening. Fall gives us a veritable cornucopia of seasonal flavors and styles, from pumpkin beers to harvest ciders to more ...

Alzheimer's drug developer Cassava Sciences (NASDAQ:SAVA) has struck a consulting agreement with its former chief executive officer, Remi Barbier, nearly two months after his resignation.

Shares of Cassava Sciences Inc. dropped more than 12% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two ...